Use of cytosar in pediatric non-Hodgkin lymphoma

✍ Scribed by Sullivan, M. P. ;Ramirez, I. ;Pullen, J. ;Moore, T. ;Doering, E. J. ;Falletta, J. M. ;Trueworthy, R. ;Chen, T.

• Publisher: John Wiley and Sons
• Year: 1982
• Tongue: English
• Weight: 320 KB
• Volume: 10
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950100726

✦ Synopsis

Cytosar, as a component of LSAz-Lz therapy, was given in combination with thioguanine in consolidation by schedules used in acute granulocytic leukemia. Daily Cytosar injections were given for 4 days in maintenance. In an effort to increase efficacy, second generation LSAz-Lz therapy employs Cytosar as continuous 5 days infusions using the autosyringe; a 14 day course of L-asparaginase is interspersed between the 2, 5 day courses. Thioguanine is deleted in consolidation and replaced by 6-mercaptopurine in maintenance. Response to therapy in terms of number attaining CR and remaining it1 CR are as follows for the pediatric NHL diagnostic categories: T-cell disease-14/15 (93%), 8/14 (57%); Large cell-9/9 (loo%), 6/9 (67%); diffuse undifferentiated 4/5 (go%), 4/4 (100%); and unclassified 3/3 (loo%), 3/3 (100%).